Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Antimicrobial Activities of Amine- and Guanidine-Functionalized Cholic Acid Derivatives

Chunhong Li, Matthew R. Lewis, Amy B. Gilbert, Mark D. Noel, David H. Scoville, Glenn W. Allman, Paul B. Savage
Chunhong Li
Department of Chemistry and Biochemistry and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew R. Lewis
Department of Microbiology, Brigham Young University, Provo, Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy B. Gilbert
Department of Microbiology, Brigham Young University, Provo, Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Noel
Department of Microbiology, Brigham Young University, Provo, Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Scoville
Department of Microbiology, Brigham Young University, Provo, Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn W. Allman
Department of Microbiology, Brigham Young University, Provo, Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul B. Savage
Department of Chemistry and Biochemistry and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.6.1347
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Compounds in a series of cholic acid derivatives, designed to mimic the activities of polymyxin B and its derivatives, act as both potent antibiotics and effective permeabilizers of the outer membranes of gram-negative bacteria. Some of these compounds rival polymyxin B in antibacterial activity against gram-negative bacteria and are also very active against gram-positive organisms. Other compounds interact synergistically with hydrophobic antibiotics to inhibit bacterial growth.

We have developed a series of cholic acid derivatives that includes compounds that act as potent antibiotics against gram-negative and gram-positive bacteria. In addition, compounds within this series effectively permeabilize the outer membranes of gram-negative bacteria, thereby sensitizing the bacteria to hydrophobic antibiotics. These cholic acid derivatives were developed (3, 4) to mimic the bactericidal behavior of polymyxin B (PMB) and the outer membrane-permeabilizing properties of truncated versions of PMB, such as deacyl PMB (10) and PMB nonapeptide (9). The cholic acid derivatives contain elements conserved among the polymyxin family of antibiotics, that is, a cluster of three amine groups and a hydrophobic chain. Cholic acid derivatives containing these two elements are potent antibiotics, while those lacking the hydrophobic chain effectively sensitize gram-negative bacteria to erythromycin, novobiocin, and rifampin.

MATERIALS AND METHODS

Antibacterial compounds.The syntheses of compounds1 to 8 have been reported previously (3, 4). Erythromycin was obtained from Aldrich Chemical Co. (Milwaukee, Wis.), and rifampin and novobiocin were obtained from Sigma Chemical Co. (St. Louis, Mo.) and were used as received.

Microorganisms.Reference strains were purchased from the American Type Culture Collection (Rockville, Md.) or Difco Laboratories (Detroit, Mich.). The following specific ATCC strains were used:Escherichia coli 25922, Klebsiella pneumoniae13883, Pseudomonas aeruginosa 27853, Salmonella typhimurium 14028, Enterococcus faecalis 29212,Staphylococcus aureus 25923, Streptococcus pyogenes 19615, and Candida albicans 90028. Bacterial strains were maintained on Mueller-Hinton agar plates (S. pyogenes and E. faecalis were maintained on Mueller-Hinton agar supplemented with 5% sheep blood), and C. albicans was maintained on Sabouraud dextrose agar plates.

Determination of MICs and MBCs.MICs and minimum bactericidal concentrations (MBCs) for bacteria were determined by a broth macrodilution method with Mueller-Hinton broth (6, 7) (Mueller-Hinton broth for S. pyogenes and E. faecalis was supplemented with lysed horse blood [6]). Sabouraud dextrose broth was used with C. albicans. Each compound was initially screened to determine its MIC range. Subsequently, concentration increments of the cholic acid derivatives were varied by the following criteria. For MICs above 10 μg/ml, increments of 5 μg/ml were used; for MICs between 1 and 10 μg/ml, increments of 1 μg/ml were used; and for MICs less than 1 μg/ml, increments of 0.1 μg/ml were used. This procedure was used in an effort to observe small differences in MICs and MBCs. Each MIC and MBC was measured a minimum of 10 times, with results varying less than 10%. The averaged results are reported.

Determination of MHCs.The cholic acid derivatives were dissolved in 0.85% saline, and the solution was diluted with Dulbecco phosphate-suffered saline and added to a 1% suspension of sheep erythrocytes. The samples were incubated for 24 h and centrifuged. The minimum hemolytic concentrations (MHCs) were determined by measuring the absorbance of the supernatant at 540 nm. The MHC of each compound was measured a minimum of 10 times, with results varying by less than 10%. The averaged results are reported.

Determination of FICs.Fractional inhibition concentrations (FICs) (1) were calculated as follows: FIC = [A]/ MICA + [B]/ MICB, where MICA and MICB are the MICs of compounds A and B, respectively, and [A] and [B] are the concentrations at which compounds A and B, in combination, inhibit bacterial growth. Synergism is defined by a FIC of <0.5. Synergy tests with erythromycin, novobiocin, and rifampin were performed by a broth macrodilution method. A concentration of 0.5 μg of rifampin/ml was used with E. coli and K. pneumoniae, and a concentration of 3 μg of erythromycin/ml was used with P. aeruginosa. In all other experiments, the antibiotics were used at 1 μg/ml. Each FIC was measured a minimum of 10 times, with results varying by less than 10%. The averaged results are reported.

RESULTS AND DISCUSSION

MIC and MBC data for the cholic acid derivatives with representative strains of gram-negative and gram-positive bacteria are shown in Table 1. Also included in the table are MICs for C. albicans. For comparison purposes, the MICs of PMB for various organisms were also measured and are presented in Table 1. The cholic acid derivatives display a range of activities, some with submicrogram-per-milliliter MICs. In addition, for many organisms, MICs and MBCs are very similar, especially with the most active compounds.

View this table:
  • View inline
  • View popup
Table 1.

MICs and MBCs of cholic acid derivatives 1 to8

The nature of the group extending from the steroid nucleus at C-17 greatly influences the activity of the compounds with gram-negative bacteria. Compounds with a hydrophobic chain (e.g., 7 and8) are potent antibiotics, while those with smaller chains extending from C-17 (e.g., 4 and 5) give higher MICs and MBCs. We have suggested (4) that the role of the hydrophobic chain is to facilitate “self-promoted transport” (2) of the compounds through the outer membranes of gram-negative bacteria, allowing access to the cytoplasmic membrane.

Compared to trends observed with gram-negative bacteria, the role of a hydrophobic chain in the activity of the cholic acid derivatives is less pronounced with gram-positive organisms because self-promoted transport is unnecessary. With a few exceptions (most notably compound4), the cholic acid derivatives shown in Fig.1 have similar activities against gram-positive bacteria.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Structures of cholic acid derivatives 1 to8.

The cholic acid derivatives are much less active against C. albicans than against bacteria. Under physiological conditions the cholic acid derivatives bear multiple positive charges and likely associate strongly with the negatively charged membranes of bacteria. The membranes of eukaryotic cells generally bear less of a negative charge than those of prokaryotes (5). Consequently, it is not unexpected that the cholic acid derivatives demonstrate decreased activity against C. albicans.

The MHCs (in micrograms per milliliter) of the compounds shown in Fig.1 are as follows: compound 1, 78; 2, 58;3, 26; 4, >100; 5, 100; 6, 5.9; 7, 29; and 8, 9.0. These results suggest that some of these compounds are well tolerated by eukaryotic cells.

The cholic acid derivatives lacking a hydrophobic chain were designed to increase the permeability of the outer membranes of gram-negative bacteria. Some of the compounds display potent synergism with hydrophobic antibiotics that ineffectively traverse the outer membranes of gram-negative bacteria (Table 2). We determined the FICs of compounds 1, 2,4, 5, and 6 with erythromycin, novobiocin, and rifampin (Tables 3 to5). Many of the FICs shown in Tables 3 to 5 are comparable to those reported for PMB derivatives (8). Compounds 3,7, and 8 are potent antibiotics alone, and therefore the FICs of these cholic acid derivatives were not determined.

View this table:
  • View inline
  • View popup
Table 2.

MICs of erythromycin, novobiocin, and rifampin alone

View this table:
  • View inline
  • View popup
Table 3.

Concentrations of compounds 1, 2,4, 5, and 6 required to lower the MIC of erythromycin and FICs of combinations

View this table:
  • View inline
  • View popup
Table 4.

Concentrations of compounds 1, 2,4, 5, and 6 required to lower the MIC of novobiocin and FICs of combinations

View this table:
  • View inline
  • View popup
Table 5.

Concentrations of compounds 1, 2,4, 5, and 6 required to lower the MIC of rifampin and FICs of combinations

The cholic acid derivatives display activities similar to those of PMB and its derivatives against gram-negative bacteria. That is, compounds containing a hydrophobic chain (PMB, 7, and 8) act as potent antibiotics and compounds lacking the hydrophobic side chain (deacyl PMB, PMB nonapeptide, 4, and 5) are effective permeabilizers of the outer membranes of gram-negative bacteria. To the extent that the cholic acid derivatives mimic the behavior of PMB, the compounds may indicate the functionality necessary for the activity of PMB. This functionality can be distilled down to an array of amines (or other basic groups, such as guanidines) oriented on one face of a hydrophobic scaffolding, with an attached acyl or alkyl chain facilitating self-promoted transport through the outer membrane.

Permeabilizers, such as compounds 4 and 5, may be useful in synergistic combination with antibiotics, such as erythromycin or rifampin, in inhibiting the growth of gram-negative bacteria, whereas alone the antibiotics are ineffective. Derivatives with a hydrophobic side chain, such as compounds 6,7, and 8, alone display low MICs with gram-negative and gram-positive strains of bacteria. However, their systemic use may be limited by their hemolytic activity. Nevertheless, due to their potent activity and simplicity, they may be well suited for topical applications.

ACKNOWLEDGMENT

Financial support from the National Institutes of Health (GM 54619) is gratefully acknowledged.

FOOTNOTES

    • Received 30 November 1998.
    • Returned for modification 22 January 1999.
    • Accepted 17 March 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Eliopoulos G. M.,
    2. Moellering R. C. Jr.
    Antimicrobial combinations Antibiotics in laboratory medicine. Lorian V. 1991 432 492 Williams and Wilkins Co. Baltimore, Md
  2. 2.↵
    1. Hancock R. E. W.
    Alterations in outer membrane permeability. Annu. Rev. Microbiol. 38 1984 237 264
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Li C.,
    2. Peters A. S.,
    3. Meredith E. L.,
    4. Allman G. W.,
    5. Savage P. B.
    Design and synthesis of potent sensitizers of Gram-negative bacteria based on a cholic acid scaffolding. J. Am. Chem. Soc. 120 1998 2961 2962
    OpenUrlCrossRef
  4. 4.↵
    1. Li C.,
    2. Budge L. P.,
    3. Driscoll C. D.,
    4. Willardson B. M.,
    5. Allman G. W.,
    6. Savage P. B.
    Incremental conversion of outer-membrane permeabilizers into potent antibiotics for Gram-negative bacteria. J. Am. Chem. Soc. 121 1999 931 940
    OpenUrlCrossRef
  5. 5.↵
    1. Matsuzaki K.,
    2. Sugishita K.,
    3. Fujii N.,
    4. Miyajima K.
    Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2. Biochemistry 34 1995 3423 3429
    OpenUrlCrossRefPubMed
  6. 6.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1997
  7. 7.↵
    National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. 1997 National Committee for Clinical Laboratory Standards Villanova, Pa
  8. 8.↵
    1. Vaara M.
    Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56 1992 395 411
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Vaara M.,
    2. Vaara T.
    Sensitization of Gram-negative bacteria to antibiotics and complement by nontoxic oligopeptide. Nature 303 1983 526 528
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Viljanen P.,
    2. Matsunaga H.,
    3. Kimura Y.,
    4. Vaara M.
    The outer membrane permeability-increasing action of deacylpolymyxins. J. Antibiot. 44 1991 517 523
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Antimicrobial Activities of Amine- and Guanidine-Functionalized Cholic Acid Derivatives
Chunhong Li, Matthew R. Lewis, Amy B. Gilbert, Mark D. Noel, David H. Scoville, Glenn W. Allman, Paul B. Savage
Antimicrobial Agents and Chemotherapy Jun 1999, 43 (6) 1347-1349; DOI: 10.1128/AAC.43.6.1347

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antimicrobial Activities of Amine- and Guanidine-Functionalized Cholic Acid Derivatives
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antimicrobial Activities of Amine- and Guanidine-Functionalized Cholic Acid Derivatives
Chunhong Li, Matthew R. Lewis, Amy B. Gilbert, Mark D. Noel, David H. Scoville, Glenn W. Allman, Paul B. Savage
Antimicrobial Agents and Chemotherapy Jun 1999, 43 (6) 1347-1349; DOI: 10.1128/AAC.43.6.1347
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS AND DISCUSSION
    • ACKNOWLEDGMENT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Cholates

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596